Skip to content

Carolyn I. Rodríguez

Butler Hospital

3 papers in the library · 51 citations · publishing 2021-2025

Papers

Ketamine’s acute effects on negative brain states are mediated through distinct altered states of consciousness in humans

Nature Communications October 19, 2023 Laura M Hack, Xue Zhang, B. Heifets et al. 20 citations

Ketamine rapidly induces altered states of consciousness, but the neural mechanisms are unclear. In a randomized, placebo-controlled study with nonclinical adults, functional neuroimaging examined brain activity during emotional tasks under placebo, low-dose (0.05 mg/kg), and high-dose (0.5 mg/kg) ketamine. Different dissociative experiences had opposing effects on right anterior insula activity: depersonalization reduced task-evoked activity by 0.39 standard deviations, while dissociative amnesia increased it by 0.32 standard deviations. These findings suggest that specific dissociative states may influence how ketamine affects brain activity, potentially informing treatment responses in depression.

Psychedelics and Psychedelic-Assisted Psychotherapy

FOCUS The Journal of Lifelong Learning in Psychiatry January 1, 2021 Collin Reiff, Elon E. Richman, Charles B. Nemeroff et al. 17 citations

A review of clinical trials on psychedelic drugs for psychiatric disorders found the strongest evidence for MDMA and psilocybin, both designated by the FDA as breakthrough therapies for PTSD and treatment-resistant depression, respectively. Evidence for LSD and ayahuasca is observational but suggests potential therapeutic effects for mood, anxiety, trauma, and substance use disorders, as well as end-of-life care. Of 1,603 articles screened, 14 well-designed trials were identified. The database remains insufficient for FDA approval of any psychedelic for routine clinical use, but continued research is warranted.

Psilocybin: From Psychiatric Pariah to Perceived Panacea

American Journal of Psychiatry January 1, 2025 Adrienne Grzenda, Gregory A. Fonzo, Aaron Wolfgang et al. 14 citations

Current evidence does not support recommending psilocybin combined with psychological support (PST) as a psychiatric treatment. More rigorous clinical trials are needed to confirm its effectiveness in larger and more diverse patient groups, determine appropriate dosing, improve blinding methods, and understand how it works and for whom it works best. Comparing it directly with other proven treatments will clarify its potential future role in treating major psychiatric disorders.